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Abstract. Recently, the use of triamcinolone acetonide (TA) injection has increased dramatically in
treatment for several ocular diseases. Among them, macular diseases such as macular edema due to
diabetic retinopathy, venous occlusive diseases, ocular inflammation and age-related macular degener-
ation (AMD) are very common vision threatening disorders and are great challenges to treat. In these
types of chronic retinal diseases, repeated intraocular injections of TA are often required which increases
the likelihood of complications. In order to achieve sustained-release, maintain therapeutic levels of TA
over longer times and reduce frequency of intravitreal injections, researchers are investigating different
implantable devices or injectable systems. However, as of yet, there is no sustained-release product for
TA available on the commercial market. This review discusses and compares different sustained-release
devices or injectable systems that are currently being developed.
KEY WORDS: conjugates/codrugs; drug delivery system; microcannulation; ocular implants;
triamcinolone.
INTRODUCTION
Triamcinolone acetonide (TA) is a synthetic corticoste-
roid structured as 9-fluoro-11b,16a,17,21-tetrahydroxypregna-
1,4-diene-3,20-dione cyclic 16,17-acetal with acetone. The
empirical formula is C24H31FO6 and molecular weight is
434.50 (1). It has 7.5-fold higher anti-inflammatory potency
than cortisone (2,3).Corticosteroids in general act through the
induction of lipocortin synthesis. Arachadonic acid, a com-
mon precursor of prostaglandins and leukotrienes (effective
mediators of inflammation), is released from membrane
phospholipids by phospholipase A2. Lipocortins inhibit the
phospholipase A2 (4,5). In addition to their anti-inflammato-
ry action, corticosteroids exhibit vasoconstrictive (6), and
anti-proliferative (7–9) effects. Corticosteroids can also inhib-
it angiogenic growth factors and choroidal neovascularization
(growth of abnormal new blood vessels from the choroidal
vasculature) in several animal studies (10). Moreover, cortico-
steroids stabilize the blood–retinal barrier (BRB) and are
used to control macular edema in several retinal diseases
(11,12). The mechanism of macular edema begins with
migration of leukocytes and vascular endothelial growth
factor (VEGF) production (13,14). The leukocytes adhesion
to endothelium disrupts tight junctions (15), which in turn
increases breakdown of BRB and vascular permeability,
causing edema (16). The corticosteroids can increase tight
junction integrity which protect the blood–ocular barrier and
decrease leakage (11,17). It has also been demonstrated that
corticosteroids have an antiapoptotic effect (18) and can
protect the retinal photoreceptors via activation of glucocor-
ticoid receptors. The eye possesses unique challenges with
respect to drug delivery especially with respect to the
posterior segment (choroid, retina, and vitreous) and treating
vision threatening diseases. TA is one of the most extensively
used drugs in the treatment of several ocular diseases which
are characterized by inflammation, edema and neovasculari-
zation. However, while the drug is effective, the drug delivery
system is not ideal and many side effects and complications
can occur. Novel and more efficient delivery systems are
being sought. To understand the current and new approaches
for delivery of drugs to the posterior segment, a closer look at
the structure as well as anatomic and physiologic barriers of
the eye is necessary.
Structure of the Eye
The wall of the eye contains three major concentric
layers (the outer, middle, and inner layers) and two fluid
chambers (aqueous and vitreous humor). Other key elements
of the eye include the cornea, pupil, lens, retina, macula, and
optic nerve. Fig. 1 shows the general anatomy of the
human eye. The sclera and cornea make up the outermost
layer. The sclera is composed of tough connective tissues with
an overlying thin, transparent membrane called the conjunc-
tiva. The cornea is a transparent dome-shaped window that
allows light to enter the eye. It is major refractive part of the
eye, is avascular and nourished by the aqueous humor and
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peripheral vessels. The middle layer consists of iris, ciliary
body, and choroid. The choroid is a vascular network which
supplies oxygen and nutrients to the outer half of the retina.
The opening of the iris is called the pupil which constricts or
dilates through the action of sphincter or dilator muscles in
response to light. At the iris base is a specialized region called
the ciliary body which produces the aqueous humor that
provides nutrients for the anterior segment. The lens also
provides refractive power and accommodation. The posterior
segment is filled with a jelly-like substance called vitreous
humor. The inner layer is the retina and has a function similar
to the film in a camera. The retina can be divided into two
regions: retinal pigmented epithelium (RPE) and neural
retina. RPE is firmly attached to the Bruch’s membrane
which is adjacent to the choroid. The neural retina contains
millions of photoreceptors of which there are two types: rods
and cones. Rods are mainly responsible for peripheral and
night vision. Cones provide color and detailed vision. A small
region with a high concentration of cone photoreceptors is
called the macula which provides fine details for reading and
sharp vision. Each photoreceptor connects by nerve fibers to
form the optic nerve. The retina has ten layers that contain
numerous, different cell types that function to capture light
rays and convert them into electrical impulses that travel
along the optic nerve to the brain where they are processed
into images.
Barriers in Ocular Drug Delivery
Ocular diseases in the anterior segment (cornea, con-
junctiva, sclera, and anterior uvea) can be treated with
conventional dosage forms such as eye drops, suspensions
and ointments. However, some diseases of the posterior
segment can not be treated with conventional drugs men-
tioned above (19). The reason is that topically applied drugs
are washed away by lacrimation; tear dilution and tear
turnover. The cornea, aqueous humor, and crystalline lens
create resistance to drug entry into the posterior segment
(20).The blood–aqueous and BRB further restrict the entry of
systemically or orally administered drugs into the posterior
segment. The blood–aqueous barrier is composed of the
endothelial cells in the uvea (consisting collectively of the iris,
choroid, and ciliary body). BRB can be classified into an
inner and outer BRB. Outer BRB is created by tight
junctions of the RPE cells that prevent the entry of even
small molecules into retina from the choroid. The RPE cells
possess various mechanisms such as transporters and efflux
pumps that prevent penetration of substances but allow
selective passage of nutrient from the choroid into the
vitreous (21–23). The inner BRB is due to the retinal vessel
endothelial cells that cause blockage of the systemic penetra-
tion of drugs. Because of such barriers, systemically or orally
administered drugs are found in non-therapeutic levels and
do not target the pathological conditions of the retina. In
order to achieve therapeutic levels, systemic or oral routes
require large doses of drugs but this often causes significant
systemic side effects (24).Therefore, direct intraocular injec-
Fig. 1. Schematic of the structure of the human eye. AC anterior
chamber.
Table I. Uses of Triamcinolone Acetonide in Therapeutics




Uveitis (98) Sub-tenon/transtenon, retrobulbar
Vernal keratoconjunctivitis (99) Supratarsal
Thyroid-associated ophthalmopathy (100) Periocular/Intraorbital
Intraocular diseases
Refractory cystoid macular edema (101) Intravitreal
Diabetic macular edema(102) Intravitreal
Macular edema associated with central retinal vein occlusion (103, 104) Intravitreal
Exudative macular degeneration (105) Intravitreal
Combined photodynamic therapy/TA for exudative macular degeneration (39) Intravitreal
Idiopathic juxtafoveal telangiectasia (106) Intravitreal
Choroidal neovascularization (CNV) associated with presumed ocular
histoplasmosis syndrome (POHS) (107)
Sub-tenon
Serous retinal detachment with Vogt–Koyanagi–Harada syndrome (VKH) (108) Intravitreal
Surgical uses
Triamcinolone acetonide assisted pars plana vitrectomy (109) Mid-vitreous cavity
Triamcinolone acetonide assisted anterior vitrectomy (110) Injection
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tion delivers the desired amount of drug and minimizes
extraocular side effects (25,26).
Triamcinonlone Acetonide in Ocular Therapy
TA is a water insoluble drug, can remain for a longer
duration in the vitreous cavity and may have longer action
following intravitreal administration compared to other
steroids that disappear with a few days (27). Moreover, TA
has been considered a comparatively safe and effective drug
in treatment of ocular diseases such as uveitis, macular edema
secondary to retinal vascular disease, and neovascularization
i.e., CNV in age-related macular degeneration (AMD) and
vitreoretinopathy (28). Many of these disorders require long
term steroid administration. The TA used in ophthalmology is
available as an injectable suspension. Some brands of TA are
Tricinolon, Tramacin, Flutex, Kenacort-A, Ledercort D,
Oncilon-A, Respicort, Rineton, Solodelf, Kenaquart, Vetalog,
Volonimat, Aristocort Acetonide and Kenalog. The most
commonly used TA is Kenalog-40 (40 mg/mL, Bristol-Myers-
Squibb, Peapack, NJ, USA). Trivaris (80 mg/mL, Allergan,
Inc. USA) and Triesence (40 mg/mL, Alcon, Inc. USA) are
recently FDA approved brands of TA for ophthalmic use. In
the past few years, use of TA has increased dramatically in
treatment for several ocular diseases and as a surgical aide
in vitreous/ocular therapies (Table I). This is also supported
by observing a drastic rise (13-fold) in the number of PubMed
citation, using a Kenalog-Intravitreal search, from 2002 to
2005 (29). Fig. 2 shows the location of ocular injections.
Macular edema that is associated with diabetic retinopathy,
venous occlusive diseases, ocular inflammation, and AMD
are very common vision threatening diseases and presents a
significant challenge in regards to treatment. Patient with
type-II diabetes mellitus are at risk of developing diabetic
macular edema (DME). Patients with a 10-year history of
diabetes have a 7–10% incidence of DME. At 20 years, its
incidence increases to 25–30%.In the presence of prolifera-
tive diabetic retinopathy (PDR), there is a 71% incidence of
DME (19). DME is characterized by swelling of the macula
due to gradual leakage of fluids from blood vessels and
breakdown of the blood-retinal barrier (30). In addition to
diabetes mellitus, hypertension can cause an increase in
hydrostatic pressure within blood capillaries resulting in leakage
of fluid into the surrounding retina. DME is of two types: focal
or non-cystoid DME and diffuse or cystoid DME. Focal edema
is associated with deposition of exudates (lipoprotein) resulting
from microaneurysms leakage. Diffuse edema represents more
extensive breakdown of the blood-retinal barrier, with the
leakage from both microaneurysms and retinal capillaries (31,
32). Clinically optical coherence tomography (OCT) is used to
Fig. 2. Schematic showing the location of different ocular injections.
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diagnose and evaluate therapeutic response following treatment
for DME (33). OCT is a noninvasive, non-contact, imaging
device used to obtain high resolution cross-sectional images of
the retina that allows the eye care professional to differentiate
normal retina from DME. Fig. 3 shows an image of a retina
with DME that has an accumulation of fluid resulting in
increased retinal thickness. The DME can be treated with
intravitreal injections of TA (IVTA) alone or in combination
with anti-VEGF medications. Due to complexity of the
responses from such vision threatening diseases, therapies that
target more than one component of the pathological condition
may show clinical benefit over single therapy. VEGF is themajor
angiogenic stimulus for neovascularization but also there is a
strong immunologic role in angiogenesis (34). Therefore, anti-
VEGF treatment can antagonize neovascularization, reduce or
stop vessel leakage, and alleviate edema where as IVTA can act
by its broad range of action discussed earlier. So the treatment
that allows interfering of both pathways would be more efficient
over monotherapy that only blocks one of the pathways.
AMD has affected nearly 15–20 million people and is the
most common cause of blindness in patients over 65 years of age
(35). There are two types of AMD (Fig. 4): dry AMD (non-
exudative/atrophic), and wet AMD (exudative/neovascular).
Age is one of the major risk factors for AMD. Other risk factors
are race, cardiovascular diseases, smoking and AMD in the
contralateral (fellow) eye. Initially, the disease begins with
formation of small-sized drusen (yellow lipofuscin deposits)
underneath the retina. Dry AMD is found in 85–90% of AMD
subjects. It is characterized by a slow breakdown of photo-
receptors, and retinal pigment epithelium (RPE) leading to
vision loss. In wet AMD, there is CNV which are fragile causing
leakage of blood and fluid into the subretinal space and
subsequent scar formation. Other characteristics of AMD
include disruption of Bruch’s membrane and degeneration of
RPE, both of which can contribute to decreased visual acuity
(36–38). The CNV can be treated by a combination therapy of
IVTA and photodynamic therapy (PDT) which acts synergisti-
cally to improve the vision and reduces the number of treat-
ments required to maintain acuity (39–44). PDT produces
oxidative radicals that cause selective toxicity for neovasculari-
zation and also affects physiology of the choroidal vasculature
(45). Following PDT treatment, there is a transient thrombotic
occlusion of adjacent choriocapillaries and increased expression
of VEGF with induction of various inflammatory mediators
(46). IVTA leads to a transient reduction in leakage from CNV,
and inhibits VEGF expression and inflammatory pathways (47).
Most recently anti-VEGF medications have been used to treat
the wet form of AMD.
The response and side effects to TA vary greatly because
individual patients can responded differently to the same doses
of TA. With recent clinical and experimental studies confirming
the pivotal role of IVTA in the successful management of
several vision affecting diseases mentioned earlier, the use of
IVTA has increased by several folds in the past 5 years (29).
However, the prolonged effects and ultimately successful
therapy depends on the retention of IVTA. The longer
retention, the longer the drug half-life. There are a number of
papers showing that a great difference in the TA half-life in the
vitreous depending on frequency of injection, concentration of
drug, animal species, and the condition of the eye (vitrectomized
Fig. 3. Retinal images of proliferative diabetic retinopathy. The OCT demonstrates a
normal retina and a retina with macular edema. The fovea is the region of high
concentration of cone photoreceptors and appears as a depression within the retina. When
DME occurs then intraretinal fluid causes thickening and the foveal pit disappears. RPE
retinal pigment epithelial cells, ONL outer nuclear layer, NFL nerve fiber layer.
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versus nonvitrectomized)(27,48,49). The intravitreally injected
drug is rapidly eliminated by the eye’s natural circulatory process
so that frequent injections may be required which are unpopular
with many patients. Therefore, large dose injections are often
required to be effective (50) but are associated with several
ocular complications/side effects including increased intraocular
pressure (IOP), cataract formation, endophthalmitis, pseudoen-
dophthalmitis and increased risk of retinal detachment (28).
Presently, investigations are underway to test the feasi-
bility of introducing TA directly into the subretinal space using
implantable devices or by injecting suspensions or microspheres
of TA that will allow sustained-release of the drug. Alterna-
tively, another approach for the injectable system includes a
novel technique of direct injection of TA into the supra-
choroidal space (SCS) in which therapeutic levels of TA can
be maintained for longer durations. If successful, the need for
frequent use of conventional injections would be reduced and
the procedure would be an option for treatment of several
vision threatening diseases. This review focuses on the work
that has been conducted for the controlled-release of TA with
emphasis on preparation of the devices, polymers used, in vitro/
in vivo performance, strengths, and weakness for each device or
injectable system (Table II).
INTRAOCULAR SUSTAINED-RELEASE DELIVERY
SYSTEM
Currently, administration of TA for different ocular
therapies is made by direct intravitreal injection. Various
researchers have studied different implantable devices or
injectable systems, many of which ultimately showed sus-
tained-release performance of TA. However, as of yet, there
is no sustained-release product for TA available on the
market although one device developed by Surmodics Inc.
(Eden Prairie, MN), is in phase I clinical trial (51). Beside TA
implants, pharmaceutical companies have developed intraoc-
ular implants using steroids other than TA as the active
ingredients or using some other drug or encapsulated cells to
treat vitreoretinal diseases (Table III). Some examples are:
1. Posurdex (Allergan Inc., USA) uses dexamethasone
(with dose of 700 μg) and is a biodegradable, micro-sized
implant which would release drug over a month. It is in
phase III clinical trials for the treatment ofmacular edema
due to retinal vein occlusion, DME, and uveitis (52).
2. Surodex (Allergan Inc., USA) uses dexamethasone
(with dose of 60 μg) and is a biodegradable, micro-
sized implant which show release performance of drug
for 7 days. It is in Phase III clinical trials for the
treatment of postoperative inflammation following
filtering surgery on eyes with glaucoma (53,54).
3. Retisert (Bausch & Lomb, Rochester, USA) has
fluocinolone acetonide as the active ingredient. This
implant is disc-shaped (3×2×5 mm) and can release
the drug up to 3 years. This implant is approved by
FDA for the treatment of chronic noninfectious
uveitis affecting the posterior segment (55).
4. Medidur (Alimera Sciences, USA and pSivida Inc.,
USA) is a tiny rod-shaped (length 3.5 mm, diameter
0.37) implant containing fluocinolone acetonide with
drug release duration of 18–36 months. It is in the
Phase III FAME (Fluocinolone Acetonide in Diabetic
Macular Edema) trial (http://www.alimerasciences.
com/medidur_overview.asp).
5. Vitrasert (Bausch & Lomb, Rochester, USA) is the
first implantable millimeter-sized device for ganciclo-
vir (an anti-viral drug) and can release the drug for
8 months. This implant is approved by the FDA to
treat patients with AIDS-related cytomegalovirus
(CMV) Retinitis (56).
6. NT-501 (Neurotech Inc., USA) is genetically engi-
neered RPE cells contained within encapsulated cell
technology (ECT). Following implantation, there is
secretion and controlled delivery of ciliary neuro-
trophic factor (CNTF) to the back of the eye. The
release duration of CNTF is 18 months and can be
used for glaucoma, CNV, and uveitis. It is in Phase II
clinical trials (57,58).
The following is a brief discussion about implantable
devices/injectable systems for TA:
Implantable Devices
Almost all implants are made of polymers and can be
classified into either biodegradable or nonbiodegradable
devices. Biodegradable polymers are gradually converted
into a soluble form through enzymatic or non-enzymatic
reactions in the body. The nonbiodegradable polymers are
not metabolized or degraded and therefore, once empty must
Fig. 4. Images of the retinal fundus from a normal eye, an eye with dry AMD and wet AMD. Note the numerous drusen in the dry AMD
fundus. The wet AMD shows a region of choroidal neovascularization (CNV) that can lead to subretinal scarring and loss of vision.






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































775Intraocular Sustained-Release Delivery Systems for TA
be removed by a second surgery which exposes the patient to
potential complications (59). This is an advantage for the
biodegradable devices in that further invasive procedures for
their retrieval are eliminated. Both biodegradable and
nonbiodegradable materials have been designed into various
forms. There are implantable devices that are shaped as flat
sheets, pellets, discs, rods, or plugs. In addition, the intra-
vitreal injectable systems are found in the forms of suspen-
sions and microspheres (60) or as a new technique that injects
the drug into the SCS. Fig. 5 summarizes the different
sustained-release implantable (nonbiodegradable, biodegrad-
able) devices for TA studied to date.
Nonbiodegradable Devices
The polymers used for nonbiodegradable devices of TA
sustained-release are polyvinyl alcohol (PVA) and ethylene
vinyl acetate (EVA). PVA is a permeable polymer that
provides the framework to regulate the rate of drug
permeation. EVA is an impermeable polymer that restricts
the device surface area through which the drug can be
released (61). The mechanism of drug release is that fluid
diffuses into the device and dissolves the drug pellet into a
saturated solution which is then released by diffusion into the
surrounding area, while the inside solution remains saturated
with drug, making release rate constant (62). The nonbiode-
gradable polymeric devices lack an initial burst of drug, and
controlled-release can be achieved for many years. Moreover,
the distribution is localized so that higher drug concentrations
are found in the vitreous compared to the aqueous humor
with the serum concentrations being the lowest (63). There
have been two recent studies for novel nonbiodegradable
devices to release TA, the microimplant and the implant.
Microimplant. Ciulla et al. (64) demonstrated that various
TA concentrations could be delivered effectively for a longer
duration from intravitreal microimplants, (square/rectangular
1×1×1/1×1×2 mm sheets) prepared using PVA polymer
matrices. An in vitro study showed 22–35 days of TA release
from these sheets. However, in vivo measurement of vitreous
concentrations of TA in the rat was not feasible because of
the small volume of the eye. To study in vivo therapeutic
effects, the TA microimplants were inserted (subretinal) into
the rat’s eyes following induction of choroidal neovascular
membranes (CNVMs) by laser treatment. In vivo evaluations
were measurement of the thickness of fibrovascular mem-
branes at various intervals. These implants inhibited fibrovas-
cular proliferation (FVP) disease for at least 35 days. It is the
first animal study using microsize TA implants. However, this
study was designed to evaluate inhibition of FVPs, but not
regression of preexisting FVPs, which more accurately reflects
the actual human CNVM condition. In this model, the rapidly
developed FVP also prevented comparisons of any subtle
difference in effectiveness between various microimplant
designs with each other. Importantly, there were no complica-
tions following microimplant insertion mentioned in the
literature.
Implant. Beeley et al. (65) studied in rabbits another
novel implantable device that is a biocompatible, sustained
release, subretinal drug delivery implant for TA. This rod-























































































































































































































































































































































































































































































































































































776 Mansoor, Kuppermann and Kenney
diameter) with an outer drug-loaded polymer coating. The
inner filament is an etched nitinol core wire that is loaded
with TA mixed with poly(methyl methacrylate) (PMMA) and
poly(ethylene-covinyl acetate). Coating of the TA with
PMMA and poly (ethylene-covinyl acetate) polymers has
been manufactured by SurModics, Inc. This type of coating
technology is being used currently in sirolimus-eluting
cardiovascular stents in human patients. As an in vivo study,
implants were surgically inserted into the subretinal space of
20/24 rabbits. The implants were evaluated on the basis of
clinical tolerability (assessed by examination) and levels of in
vivo drug elution. It was a preliminary study using the
prototype implant and coating technology by SurModics
polymer. The implants were found to be well tolerated and
could elute TA for 4 weeks. However, during a 4 weeks
follow-up period, although good retinal tolerance was ob-
served, cataract and corneal edema developed in six
implanted eyes.
Devices in Clinical Trial. SurModics Inc. has a delivery
system using I-vation technology capable of delivering TA on
a sustained-release basis. There are two I-vation TA for-
Fig. 5. Schematic of intraocular implantable devices. a Nonbiodegradable devices. b Biodegradable devices.
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mulations: slow- release (~1 μg per day), and fast-release
form (~3 μg per day). In the I-vation intravitral implant, there
is a helical coil coated with TA and polymer. The polymers
are PMMA and poly (ethylene-covinyl acetate) similar to the
previously discussed implant. The advantages of this implant
are the unique helical design (approximate length of 0.5 mm
and width of 0.21 mm) that maximizes the surface area
available for drug delivery, ensures secure anchoring of the
implant at the scleral wall and facilitates ease of its retrieval.
It is predicted that this implant will have an in vivo sustained
delivery for a minimum of 2 years. Safety and biocompatibil-
ity of this implant have been studied extensively in a
preclinical rabbit model. The implants were placed in more
than 100 rabbit eyes and followed clinically for 9 months post-
implantation. Results showed that implants were well toler-
ated, with no observed retinal toxicity and very little fibrous
encapsulation of the implant. Removal of the implant was
straightforward involving a small incision through which the
implant could be extracted. Presently, I-vation is in Phase 1
human clinical trials in patients with DME. This is the device
with the longest release history studied yet. If successful, I-
vation could replace the need for multiple intravitreal
injections and would be a major arsenal to treat both diabetic
retinopathy and AMD (51,66). However, implant retrieval
would be needed in all cases.
The nonbiodegradable implants are a popular choice for
sustained-release ophthalmic drug delivery because they offer
adjustable drug release profiles and have a proven clinical
efficacy. However, these nonbiodegradable implants are not
the only choice available since there is rapidly advancing
technologies in other polymeric systems such as biodegradable
implants and microspheres.
Biodegradable Devices
Devices for intraocular sustained-release of TA have
been studied using limited biodegradable polymers. The most
popular polymers include poly(lactic acid) (PLA), poly
(glycolic acid) (PGA), and their copolymer, poly(lactic-co-
glycolic acid) (PLGA). Some implants also use polycaprolac-
tones (PCL) and poly(methylidene malonate) (PMM2.1.2)
polymers. In general, the biodegradable polymers degrade
through enzymatic and nonenzymatic hydrolysis of polymeric
chains (67,68) and as a result, sustained drug release is
achieved. Importantly, the release rates can be manipulated.
However, the release performance (of drugs) is shorter as
compared to nonbiodegradables devices.
Multiple-Drug Implant. Sustained delivery of multiple
drugs from a single implant has also been investigated. Zhou
et al. (69) fabricated a multiple-drug delivery system to treat
proliferative vitreoretinopathy (PVR). For this implant,
PLGA was chosen as the matrix material. In the last two
decades, PLGA has been found to have well-proven biocom-
patibility, biodegradability (70) and manipulatable release-
rate and has received FDA approval as an implantable
material (71). Furthermore, the PLGA degradation products,
lactic and glycolic acids are metabolized through the Krebs
cycle to carbon dioxide and water. These physical properties
have made PLGA highly attractive for the controlled delivery
of drugs (72). The cylindrical implant (7 mm long and 0.8 mm
diameter) had three parts containing 5-fluorouridine (5FUrd),
TA, and tissue plasminogen activator (t-PA). This implant
released 5FUrd and TA over 4 weeks and the t-PA over
2 weeks. It was the first designed and studied device with
multisegment (for different types of drug) in a single implant.
The multisegment design, unlike conjugates allows indepen-
dent release of individual drugs without affecting the release
rate of the other drugs. However, while this regimen approach
has undergone a preliminary in vitro controlled-release study
for the management of PVR, the system needs in vivo
evaluation and optimization of the release performance.
Single-Drug Implant. In another study, Beeley et al. (68)
evaluated an implant made of PCL polymer for delivery of
TA. PCL degrades over a longer period than PLGA which
would allow for a longer duration delivery. The rod-shaped
implant (2 mm in length and 320 μm in diameter) was made
by embedding the TA within PCL at different polymer/drug
ratios. In vitro analysis demonstrated 1 month elution
capabilities of TA from the implant. For the in vivo study,
the implants were surgically placed into the subretinal space
of six rabbits and observed for drug release and complications
for 4 weeks. The TA was released for 4 weeks and no
complications were observed during the 4 weeks follow-up
period. Histologically, there were no signs of inflammation
due to the presence of the PCL polymer, thereby demon-
strating its excellent biocompatibility with retinal tissues. The
tissue TA drug levels were localized to the posterior eye
segment and not detected in the anterior ocular structures or
blood. However, the insertion of the implant although not
difficult caused mechanical damage to the cellular layers. In
addition, the possibility of retinal toxicity from the PCL
breakdown products needs further long-term evaluation.
Scleral Implants. Felt-Baeyens et al. (73) developed
ocular scleral implants to study sustained release of TA.
Disc-shaped implants 8 mm in diameter with thickness of
1 mm were manufactured using PMM2.1.2 which is a
relatively new synthetic polymer. The advantage of
PMM2.1.2 as an implant is that it breaks down into nontoxic
ethanol and glycolic acid (74,75). Following implantation into
rabbit eyes, the scleral implants showed good ocular biocom-
patibility. The numbers of inflammatory cells and protein
content in aqueous humor were low, indicating that these
implants were well tolerated. The in vivo therapeutic
concentrations of TA were found in the vitreous for 5 weeks
and detectable levels were present for up to 8 weeks, thereby
demonstrating sustained release of TA. Moreover, high con-
centrations (up to 500 ng/mg of tissue) of TAwere found in the
sclera, confirming it as the drug reservoir and sustained-release
site. In conclusion, this study showed the scleral route as a
potential reservoir for drugs used for the treatment of the
posterior segment diseases, thus minimizing side effects
associated with the systemic route. However, these results
need to be confirmed by complete pharmacokinetic studies
following implantation on a larger population of rabbits.
Drug Delivery System Associated with Artificial Lens. Very
recently, an extended release device of TA and its efficacy with
respect to reduction of post-operative inflammation in a rabbit
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model has been reported. Eperon et al. (76) developed a TA
loaded biodegradable drug delivery system (DDS) combined
with an artificial intraocular lens (IOL, 6.0 mm in diameter)
called IOL+DDS. DDS loaded TAwas produced as a disc 2 mm
in diameter using PLGAwith different molecular weights. The
higher the molecular weight of PLGA, the slower was the
release of TA from discs in vitro. For placement into eyes, one to
three discs were threaded onto an IOL haptic. Cataract surgery
was then performed on the rabbits eyes and an IOLwith one, or
two/three discs (IOL+1, 2/3 DDS with TA load) tied along the
haptic was inserted. Using two DDS per IOL, the in vivo TA
release was for 12 weeks. The protein concentration and
inflammatory cell levels within aqueous humor showed that
IOL+DDS was biocompatible and tolerated. One loaded DDS
significantly reduced postoperative ocular inflammation. Two/
three loaded DDS effectively inhibited inflammation up to
84 days. No complications were reported in this study. An
advantage of the IOL+DDS is that it combines cataract surgery
and postoperative treatment in a single procedure. Another
advantage is its release of low drug concentrations that are
effective and have few side effects (77). Moreover, patient non-
compliance as well as the need for a second surgery to remove
the implant is eliminated. Therefore, IOL+DDSmay be suitable
for incorporation of other drugs (steroids, ganciclovir, anti-
biotics etc.) for treatment of the various sight threatening
diseases. The technique may also be useful in AMD patients
that face cataract surgery since some studies report a progres-
sion of AMD after cataract removal. Theoretically, the implant
with either a steroid or anti-VEGF drug might decrease the
likelihood of post-surgical AMD progression.
Injectable System/Particles
There are some preliminary studies to develop a
technique of sustained-release TA using conjugate/codrug
design. In conjugate/codrug systems, there is no use of
polymers that can cause incompatibility and toxicity (78–80).
In addition, the volume of injected conjugate/codrug can be
small, so the concerns of polymeric load (81) to the eyes are
eliminated. Also, this system does not include surgery,
therefore is preferred by the patient (78–80). Using this
system, TA is conjugated/combined with drugs such as 5-
fluorouracil (5-FU) or mitomycin C (MMC). The conjugates
are designed by covalently linking two drugs whereas codrug
are formed either by simple mixing or compressing two drugs
together. The conjugate dissolves slowly and is hydrolyzed,
giving sustained-release of TA.
Another development is the intraocular injection of
microspheres to reduce the need for multiple intravitreal
injections and/or surgical implantation of sustained-release
devices. Microspheres provide a sustained-release injectable
drug depot formulation that, in some cases, is able to target
specific tissues. The microspheres range in size between 1 and
1,000 μm in diameter and are made with either PLA or
PLGA polymers (82–89).
Very recently, a novel injection method was developed
that involves “microcannulation” into the suprachoroidal
space (SCS) of the eye. The injected TA, delivered by
microcannula, was retained for a longer period in the
posterior segment of the eye.
The following briefly describes the intraocular injectable
systems used for sustained-release/retention of TA:
Conjugates/codrugs
Berger et al. (78) reported a sustained drug delivery
system of a TA and 5-FU conjugate that lacks any polymer
component. The TA-5-FU conjugate (as a pellet) was injected
intravitreally into the rabbit’s eye following induction of
proliferative vitreoretinopathy (PVR). There was sustained-
release of TA and 5-FU for 1 month, which effectively
inhibited the progression of PVR in this animal model. The
conjugate system allowed for sustained-release of multiple
drugs each of which can target different mechanisms of the
disease and thereby improve healing efficiency. However, the
rabbit model used in this study was not ideal for simulating
the human condition because of the absence of vitrectomy
and/or extended intraocular tamponade of gas or silicon oil in
the model which is typically used after surgery for PVR in
humans. It is unclear how the release rate of TA-5-FU
conjugate would be impacted by these conditions.
Macky et al. (79) synthesized a TA and MMC (TA-
MMC) conjugate with a half-life of 23.6 h in aqueous solution.
An in vitro study using this conjugate showed sufficient
antiproliferative activities in a fibroblast cell line and its
intravitreal injection into a rat eye model did not show any
toxicity. However, the efficacy of TA-MMC conjugates in
inhibiting proliferative diseases in animal/human eyes has yet
to be studied. MMC is comparatively more toxic at higher
concentrations; therefore, its release rate from any conjugate
system must be manipulated to achieve the minimum vivo
level needed for therapeutic effect.
Yang et al. (80) reported efficacy of an intravitreal
sustained-release TA/5-FU codrug formulated as either an
injectable powder for injection or a pellet for implantation for
the treatment of an experimental PVR rabbit model. The
codrugs of TA/5-FU powder and TA/5-FU pellet were
prepared by direct compression of the powdered drug. For
an in vivo study, the TA/5-FU powder was injected directly
into the vitreous cavity where as the TA/5-FU pellet was
implanted into vitreous cavity following PVR induction. Both
the pellet and powder codrug systems showed sustained-
release of TA and 5-FU and effectively inhibited progression
of PVR in this rabbit model. The intact codrug in the vitreous
cavity could be measured by 12 weeks and no drug-related
toxic effects were found by either clinical or histopathologic
examination. Future use of the codrug may include prophy-
lactic injection at the time of primary scleral buckle to repair
a rhegmatogenous retinal detachment, or following vitrecto-
my to repair a primary or recurrent rhegmatogenous retinal
detachment in the presence or absence of PVR.
Microspheres
In general, microspheres are prepared by methods
similar to preparing emulsions. That is, the first drug is
suspended or dissolved in a non-aqueous (organic) solvent
containing a polymer and is then mixed slowly with the
aqueous solution containing surfactant. This mixing yields
either an oil in water (o/w) or oil in oil (o/o) emulsion. Then
the non-aqueous solvent is evaporated by heat or vacuum
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resulting in a suspension of solid microspheres loaded with
the drug. Higher encapsulation efficiencies for hydrophilic
drugs are obtained by o/o emulsion where as for lipophilic
drugs the o/w emulsion is preferable. Drug release from
microspheres depends on several factors such as polymer
composition and its molecular weight, drug hydrophilicity,
drug loading, as well as microsphere size (60). Furthermore,
the drug release rate from small microspheres is faster than
larger ones (84).
Cardillo et al. (90) reported human studies of a con-
trolled-release microsphere system for TA (referred in this
study as the RETAAC system). RETAAC prepared with
PLGA was injected intravitreally into patients with diffuse
DME and their efficacy compared to direct TA-injections.
Both the safety as well as the anatomic and functional
outcomes was evaluated. RETAAC-treated eyes showed
marked decrease of retinal thickness as well as improved
visual acuity (VA) for 12 months. This study demonstrated a
superior long-term pharmacologic performance compared to
TA-injected eyes. RETAAC was found to be safe and well
tolerated by the retina. The advantage of the RETAAC
system is that they are erodible devices, can be delivered by
use of simple injection and no scleral placement is required.
No drug or procedure related side effects were observed in
this study. Since, RETAAC is minimally invasive; it may be a
feasible delivery system for sustained therapeutic quantities
of TA to the retina. This would increase the duration of
therapeutic effects compared to the conventional formula-
tions and pellet systems. Therefore, RETAAC is a promising
technique for the intraocular delivery of multiple drugs for
the treatment of chronic posterior segment diseases. Howev-
er, the disadvantage of this study is the small sample size
(nine patients) and therefore additional investigations using
large populations are necessary. Moreover, there was no
report regarding pharmacokinetics of TA in this study.
Microcannulation
Intravitreal injections are reasonably well tolerated.
However, limitations of intravitreal injections include the
need for multiple injections, possible complications and the
need for frequent follow-up visits to the physician. Also,
more sustained delivery systems are needed for treatment of
chronic eye diseases. Vitreous implants showed sustained-
release performance of the drug but needed intraocular
surgery for their placement (91–93). In addition, the devices
are expensive and may need further surgical treatment for
their removal or replacement (94). Olsen et al. (95)
described a novel posterior drug delivery system (PDS) by
means of microcannulation to SCS. Initially, cadaveric
human eyes were studied and then the procedure was
further optimized using two animal models; pigs and
primates. The SCS is bound anteriorly by the scleral spur
and posteriorly by the connections between the choroid and
short posterior ciliary vessels. The microcannulation system
takes into account the distinct anatomical boundaries of the
SCS. The microcannula (325 μm outer diameter×175 μm
inner diameter) used for this system is a flexible steel wire
shaft and a fiber optic light source. To introduce the
cannula, two parallel radial scleral incisions are used to
expose the choroid and a second sclerotomy is made for the
illuminated endoscope. A wide angle viewing system allows
visualization by the surgeon. After placement of drug into
the SCS, the scleral and conjunctival incisions are closed
using 7–0 vicryl suture.
The TA retention was 120 days in the retina, choroid and
vitreous with minimum elevation of systemic levels in either
model. Histopathology demonstrated normal anatomy in
uncomplicated cases. The advantages of this methodology
are: (1) direct visualization of the cannula tip and the site of
drug delivery, even through pigmented tissues; and (2) direct
visualization of the drug bolus entering the SCS. In addition,
this method may be applicable to a wide variety of
pharmacotherapies for the macula, optic nerve, and posterior
pole. But the limitations of this study are that micro-
cannulation may not be feasible because it involves numerous
surgical steps and manipulation. For example, it uses a steel
wire shaft which can lead to mechanical damage, two scleral
incisions and a sclerotomy that requires a suture after the
placement of drug. All of these may be sources for potential
complications for this methodology. Moreover, further
clinical studies will be necessary to evaluate this technology
for its potential in the management of posterior segment
diseases.
SUMMARY AND CONCLUSION
The crucial need to limit the frequency of repeated
intraocular injections for the treatment of AMD, DME or
chronic intraocular inflammation has enhanced the need for
the development of slow-release devices. As described in this
review, most of the developed devices showed sustained-
release of TA and induce marked therapeutic effects on
experimentally induced eye diseases. However, polymer
degradation in the implants may cause toxicity and the need
for challenging surgical techniques has hampered the further
development of these systems for routine clinical use.
Therefore, additional studies to develop safe, innovative,
efficient, sustained-release devices/system for TA should be
pursued in order to provide novel therapies to treat chronic
diseases of posterior segment of the eyes.
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